BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261027T140000
DTEND;TZID=America/New_York:20261027T170000
DTSTAMP:20260918T090753
CREATED:20260629T174707Z
LAST-MODIFIED:20260916T210600Z
UID:3099-1793109600-1793120400@lifescievents.com
SUMMARY:LB Pharma R&D Day: Advancing LB‑102 with a Focus on Schizophrenia Treatment
DESCRIPTION:Join LB Pharmaceuticals for an in-person and virtual R&D Day featuring Roger S. McIntyre\, MD\, FRCPC (University of Toronto)\, alongside Heather Turner (CEO)\, Susan G. Kozauer (CMO)\, Kaya Pai Panandiker (CCO)\, Gad Soffer (COBO)\, and Joe Miller (CFO)\, as the Company looks ahead to its upcoming topline data readout in schizophrenia. \nLB-102 is a novel\, once-daily oral selective antagonist of D2\, D3 and 5HT7 receptors with a unique bimodal mechanism. It is being developed by LB Pharma for the treatment of schizophrenia\, bipolar depression\, the adjunctive treatment of major depressive disorder\, as well as other neuropsychiatric disorders\, and has the potential to be the first therapy with this unique mechanism approved for neuropsychiatric disorders in the United States. \nTopics will include: \n\nNew scientific insights on LB-102’s unique mechanism of action that underlies the emerging clinical profile and opportunity across a wide variety of brain disorders\nDiscussion of the Phase 3 trial program in schizophrenia\, its upcoming topline data readout in the first half of 2027\, and ongoing pre-commercial planning activities\n\nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/gj28t6w/.
URL:https://lifescievents.com/event/gj28t6w/
LOCATION:Midtown\, New York and Live Webcast\, Midtown\, New York and Live Webcast
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/06/LB-Pharma-Banner.png
END:VEVENT
END:VCALENDAR